New drug combo tested for Tough-to-Treat blood cancer
NCT ID NCT04850599
Summary
This study is testing a combination of three drugs—isatuximab, carfilzomib, and pomalidomide—for adults with multiple myeloma that has come back (relapsed) or stopped responding to treatment (refractory). The goal is to see if this combination can control the cancer and for how long, while closely monitoring side effects. It is for people who have had at least one prior treatment for their myeloma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.